Board of Directors
Shenda Baker, PhD
Dr. Shenda Baker is an experienced entrepreneur and scientist with expertise in polymer physics, macromolecular and surface chemistry and nanostructured materials. Dr Baker served as CEO for Synspira, bringing the first Synedgen licensed technology into clinical trials for inhaled treatment for patients with cystic fibrosis. Dr. Baker was a professor of Chemistry at Harvey Mudd College from 1991-2014 with a research focus on polymer nanostructures and self-assembly at liquid and solid interfaces. She has held strategic positions on the Board of Directors of the Materials Research Society and has served on advisory boards with the National Institutes of Health at the National Institutie for Dental and Cranofacial Research, National Science Foundation at the directorates of Math and Physical Sciences, Computer and Information Science and Engineering, the Advisory Committee for Cyber Infrastructure and at the Department of Energy. Dr. Baker is a member of the American Chemical Society and the Materials Research Society and currently serves on the Advisory Council of the National Institute of Dental and Craniofacial Research of the NIH. She is co-inventor on all of the Synedgen technology.
Dan is a co-founder and Chief Executive Officer of Equillium, and Chairman of the Board of Directors. He also serves as the Managing Member of BioBrit, a life sciences consulting and investment firm. Prior to co-founding Equillium, he served as the President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes, and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Before joining Amylin, Dan worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Intercept Pharmaceuticals and a number of private companies and philanthropic organizations.
Kenton Gregory, MD
Dr. Kenton Gregory is executive director of the Oregon Medical Laser Center at Providence St. Vincent in Portland, Oregon. He is a practicing interventional cardiologist and recipient of the first endowed chair in laser medicine and surgery. He is the founder and President of Oregon Biomedical Engineering Institute, an R&D company, and Biomedical Research Services, a scientific and technical consulting company. Dr. Gregory serves as an associate professor of biomedical engineering at the Oregon Graduate Institute of Science and Technology and an assistant professor of medicine at Oregon Health and Science University. He has been Principal Investigator on 5 FDA sponsored clinical trials and received over $30 million in grants to research novel techniques for the repair and replacement of tissues.
Paul C. Grint, MD
Paul Grint was most recently CEO and a member of the board of directors of AmpliPhi Biosciences, which recently merged with C3J Therapeutics to form Armata Pharmaceuticals. Dr. Grint has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. Dr. Grint has also served in senior management roles at Cerexa, Forest Laboratories, Kalypsys, Pfizer, IDEC Pharmaceuticals, and Schering-Plough Corporation. He is currently a board member at Amplyx Pharmaceuticals, Inhibikase Therapeutics and Synedgen. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and holds a bachelor’s degree from St. Mary’s Hospital, University of London and a medical degree from St. Bartholomew’s Hospital, University of London.
Andrew W. Miller
Andrew Miller is the President and CEO of Stimson Lumber Company in Portland, Oregon. Stimson is an integrated timberland and wood products manufacturing company with operations in the northwestern U.S. Prior to joining Stimson in 1991, Mr. Miller was employed in the Forest Products Industry with Plum Creek Timber and Weyerhaeuser. Mr. Miller serves on multiple regional and national industry association Boards, and several non-profit Boards in the Portland area.
William Wiesmann, MD
Dr. Wiesmann is an accomplished physician, medical scientist, and program manager with experience in cell biology, systems biology, medical device development and extensive experience leading and conducting basic scientific and medical research. He served as the Director for Combat Casualty Care at the U.S. Army Medical Research and Materiel Command Post, at Ft. Detrick, where he led the design and development teams that produced novel technologies for improved battlefield survival until he retired from the Army as a colonel in 1997. His innovations, which include the LSTAT Transportable Life Support System, the Advanced Surgical Suite for Trauma Casualties (ASSTC), the SAVe ventilators, and the HemCon hemostatic bandages, have transformed medicine both on the battlefield and in civilian trauma centers. In 2004, the military named the 4-by-4-inch HemCon bandage one of the year’s “Top 10 Greatest Inventions” for its ability to stop seriously wounded soldiers from bleeding to death. He holds 59 awarded or pending patents from his work in biosensors, automated diagnostic devices, advanced tissue engineering, wound care, and infection control. Dr. Wiesmann has been published in more than 75 peer-reviewed medical journals.
Dr. Wiesmann has received many honors for his development work in government, including the US Army Meritorious Service Medal, the US Army R & D Achievement Award, and the Army Commendation Medal. He was awarded an honorary Doctor of Science degree from the University of Cincinnati.
He is a co-founder of Hawaii Chitopure, BioSTAR West, Tissue Genesis, AutoMedx Inc., and Synedgen, Inc.
Dennis Fenton, PhD
Dennis Fenton, PhD, an industry pioneer, has over three decades of experience in biotechnology. Dr. Fenton retired after a lengthy and distinguished career with Amgen, where he held a variety of notable roles, including Executive Vice President, Operations. Prior to Amgen, he was a senior researcher with Pfizer. Dr. Fenton most recently served on the board of directors of Hospira, Dendreon Corporation, Genzyme, Kythera Biopharmaceuticals, XenoPort, Nora Therapeutics and Amira Pharmaceuticals. He is an alumnus of Rutgers University, where he graduated with a Ph.D. in microbiology. Dr. Fenton currently serves as a member of the board of directors for Portola Pharmaceuticals, AnaptysBio, Cirius Therapeutics, and Modern Meadows.